Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefcapene is an oral third-generation cephalosporin antibiotic of the cephem class. It acts by inhibiting bacterial cell wall synthesis, exerting its antibacterial effect primarily through binding to penicillin-binding proteins (PBPs), which are essential for peptidoglycan cross-linking in the bacterial cell wall. This leads to cell lysis and death of susceptible bacteria. Cefcapene is used to treat a wide range of infections, including skin, respiratory tract, urinary tract, gynecologic, ophthalmic, otolaryngologic (ear/nose/throat), dental, and oral surgical infections[1][2]. It is marketed as the pivaloyloxymethyl ester prodrug (cefcapene pivoxil hydrochloride) to enhance oral bioavailability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefcapene.